CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 90 enrolled
Drug / intervention
Betaine +3 moredrug
Likely dose
Betaine 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00348933
NCT00348933N/ACompleted
CompareCT.gov

Efficacy of a Therapeutic Treatment Trial in Angelman Syndrome

University of California, San Diego·interventional·Posted Jul 6, 2006·Updated Sep 24, 2012

In Brief

A clinical study evaluating Betaine, Creatine, and 2 other interventions for Angelman Syndrome and Nervous System Diseases. Completed, enrolled 90 participants across 4 sites.

Detailed Summary

Angelman syndrome (AS) is a complex genetic disorder that affects the nervous system. The purpose of this study is to determine the effectiveness of certain dietary supplements in treating the symptoms of AS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAngelman Syndrome, Nervous System Diseases
CountriesUnited States
CollaboratorsBaylor College of Medicine, Rady Children's Hospital, San Diego, Boston Children's Hospital, Greenwood Genetic Center, Rare Diseases Clinical Research Network

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 6, 2006
Enrollment StartJul 1, 2006
Primary CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 20.0 years ago

Interventions

Betainedrug

100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses

Creatinedrug

200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses

Metafolindrug

0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses

Vitamin B12drug

1 mg by mouth per day for all weights and ages